Blogs

A new report from the US Congressional Budget Office (CBO) estimates a $4.8 billion savings would result from banning settlements between brand name drugmakers and generic companies to delay generic versions of innovator medicines. The savings from banning the so-called “pay-for-delay” deals was calculated by CBO for a 10-year period and is nearly double previous estimates of around $2.6 billion from CBO last year and $2.67 billion from the Federal Trade Commission just last month.

Read more:

• CBO Says Pay To Delay Bill Can Save $4.8 Billion (Pharmalot)
• CBO: Pay-to-delay ban could save $4.8B (FiercePharma)
• CBO ups savings estimate for ban on deals between drug companies (The Hill)
• FTC Renews Call for Pay-for-delay Ban (RAPS Newsroom)